drugset / Trial / NCT02406872

A Study Comparing Remimazolam Tosilate and Propofol for Intravenous General Anaesthesia in Operations

NCT02406872

Phase 2 Completed 144 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedParallel-groupDouble-blind

Summary

The purpose of this study is to find out the optimal dose for Remimazolam Tosilate as an intravenous general anaesthetic drug in operations and to determine its efficacy and safety profile comparing to propofol.

Timeline

Start
2014-12
Primary completion
2015-08
Completion
2015-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Propofol Small molecule 2 mg/kg Intravenous
Comparator Propofol Small molecule 2.5 mg/kg Intravenous
Subject Remimazolam Small molecule 6 mg/kg Intravenous
Subject Remimazolam Small molecule 12 mg/kg Intravenous
Subject Remimazolam Small molecule 18 mg/kg Intravenous

Indications

No indication recorded.